Free Trial

Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts

Halozyme Therapeutics logo
$46.96 -0.36 (-0.76%)
(As of 12/20/2024 05:31 PM ET)
Get Halozyme Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Halozyme Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

HALO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

HALO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Halozyme Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20243$0.58$0.77$0.69 
Q2 20243$0.68$0.92$0.78 
Q3 20243$0.91$1.07$0.98 
Q4 20243$0.94$1.25$1.11 
FY 202412$3.11$4.01$3.56 
Q1 20251$0.97$0.97$0.97 
Q2 20251$1.07$1.07$1.07 
Q3 20251$1.14$1.14$1.14 
Q4 20251$1.30$1.30$1.30 
FY 20254$4.48$4.48$4.48 
Q1 20261$1.40$1.40$1.40 
Q2 20261$1.41$1.41$1.41 
Q3 20261$1.44$1.44$1.44 

Halozyme Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/6/2024Q2 2024$0.73$0.91+$0.18$0.98$204.94M$231.40M
5/7/2024Q1 2024$0.64$0.71+$0.07$0.82$201.72M$195.88M
2/20/2024Q4 2023$0.77$0.75 -$0.02$0.85$235.25M$230.04M
11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47M$216.03M
8/8/2023Q2 2023$0.59$0.68+$0.09$0.80$201.91M$221.04M
5/9/2023Q1 2023$0.44$0.43 -$0.01$0.57$174.20M$162.14M
2/21/2023Q4 2022$0.43$0.44+$0.01$0.46$186.07M$181.50M

Halozyme Therapeutics Earnings - Frequently Asked Questions

Halozyme Therapeutics updated its FY 2024 earnings guidance on Thursday, October, 31st. The company provided EPS guidance of 4.000-4.200 for the period, compared to the consensus EPS estimate of 3.960. The company issued revenue guidance of $970.0 million-$1.0 billion, compared to the consensus revenue estimate of $983.9 million.

Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $947.36 million.

Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $3.02 earnings per share over the last four quarters.

Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 15.55 and a forward price-to-earnings ratio of 12.36. The price/earnings-to-growth ratio is 0.43.

Halozyme Therapeutics's earnings are expected to grow from $3.80 per share to $4.55 per share in the next year, which is a 19.74% increase.

More Earnings Resources from MarketBeat



This page (NASDAQ:HALO) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners